Fomivirsen Sodium Patent Expiration
Fomivirsen Sodium is Used for treating CMV retinitis through intravitreal administration of a phosphorothioate oligonucleotide targeting CMV mRNA. It was first introduced by Novartis Pharmaceuticals Corp
Fomivirsen Sodium Patents
Given below is the list of patents protecting Fomivirsen Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vitravene Preservative Free | US5442049 | Oligonucleotides for modulating the effects of cytomegalovirus infections |
Aug 15, 2012
(Expired) | Novartis |
| Vitravene Preservative Free | US5595978 | Composition and method for treatment of CMV retinites |
Aug 15, 2012
(Expired) | Novartis |